Inhibiting angiogenesis by oral immunisation with poly(1-caprolactone)- poly(ethylene glycol)-poly(1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor

Attempts to neutralise basic fibroblast growth factor (BFGF) have met some success in blocking neovascularisation. The authors describe an oral protein vaccine based on human BFGF encapsulated poly(ε-caprolactone)εpoly(ethylene glycol)εpoly(ε-caprolactone) (PCEC) nanoparticles. The human BFGF encapsulated PCEC nanoparticles (BFGF/PCEC) were monodisperse with the mean diameter of 142εnm and can slow-released BFGF in vitro. After mice were orally immunised with four dosages of BFGF/PCEC nanoparticles, BFGF-specific autoantibody titer in sera was 1600. Furthermore, alginate-encapsulated tumour cell assay implied that oral immunisation with BFGF/PCEC efficiently inhibited angiogenesis in vivo. Thus, oral immunisation with BFGF/PCEC nanoparticles may be a novel strategy to suppress angiogenesis, and this vaccine may have promising application in cancer immunotherapy.